Find clinical trials for Pancreatic Cancer in Durham, NC
CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones
Related conditions:
Pancreatic Cancer trials near Durham, NC, USA:
This phase II study evaluates how well pemigatinib works for the treatment of adult patients with pancreatic cancer that has spread...
Phase 2
Raleigh, North Carolina, United States and 108 other locations
phosphorylase (MTAP)-deleted gastrointestinal, biliary tract, or pancreatic cancers. The study also aims to determine the safety...
Phase 1
Durham, North Carolina, United States and 76 other locations
This phase I study is designed to establish the safety, maximally tolerated dose (MTD) and recommended phase II dose (RP2D) of the ERK inhibitor ulix...
Phase 1
Chapel Hill, North Carolina, United States of America
TNG462-C102 is a Phase 1/2, open-label, multicenter study designed to determine the safety, tolerability, PK, PD, and preliminary antineoplastic acti...
Phase 1, Phase 2
Chapel Hill, North Carolina, United States of America and 17 other locations
is to evaluate the safety and tolerability of RMC-9805 as monotherapy and in combination with RMC-6236 in adults with KRAS G12D-mutant solid tumors...
Phase 1
Durham, North Carolina, United States and 16 other locations
The purpose of this study is to characterize the safety and tolerability of ALTA3263 in adults with advanced solid tumors with KRAS mutation...
Phase 1
Durham, North Carolina, United States and 11 other locations
cancer, gastroesophageal junction cancer (GEJ cancer) or pancreatic cancer. GEJ is where the tube that ...
Phase 1
Durham, North Carolina, United States and 45 other locations
The purpose of this study is to evaluate the safety and efficacy of a novel RAS(ON) inhibitor compared to standard(s) of care (SOC) treatment.
Phase 3
Durham, North Carolina, United States and 59 other locations
The purpose of this platform study is to evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary antitumor activity of novel RAS(ON...
Phase 1, Phase 2
Durham, North Carolina, United States and 31 other locations
and efficacy of 9-ING-41, a potent GSK-3β inhibitor, as a single agent and in combination with cytotoxic agents, in patients with refractory cancers...
Phase 2
Durham, North Carolina, United States and 65 other locations
Clinical trials
Research sites
Resources
Legal